BRAF and neoplasm: We evaluated the assay in 6 different tumor types procured from commercial sources for the assay validation and compared our KBN-SNPE (KRAS, BRAF, NRAS Single Nucleotide Primer Extension) mutation assay results to Sanger sequencing and NGS.